Cargando…

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy

Control of oxidative stress in the bone marrow (BM) is key for maintaining the interplay between self-renewal, proliferation, and differentiation of hematopoietic cells. Breakdown of this regulation can lead to diseases characterized by BM failure such as the myelodysplastic syndromes (MDS). To bett...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodríguez-García, Alba, Morales, María Luz, Garrido-García, Vanesa, García-Baquero, Irene, Leivas, Alejandra, Carreño-Tarragona, Gonzalo, Sánchez, Ricardo, Arenas, Alicia, Cedena, Teresa, Ayala, Rosa María, Bautista, José M., Martínez-López, Joaquín, Linares, María
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912333/ https://www.ncbi.nlm.nih.gov/pubmed/31652983 http://dx.doi.org/10.3390/antiox8110508

Ejemplares similares

Protein Carbonylation and Lipid Peroxidation in Hematological Malignancies
por: Rodríguez-García, Alba, et al.
Publicado: (2020)

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2023)

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2019)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021)

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome
por: Polat, Asude Kara, et al.
Publicado: (2017)

Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up
por: IMPROTA, SALVATORE, et al.
Publicado: (2013)

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse
por: Onecha, Esther, et al.
Publicado: (2020)

Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma
por: Rodríguez-García, Alba, et al.
Publicado: (2022)

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
por: Ortiz-Ruiz, Alejandra, et al.
Publicado: (2021)

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2017)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2018)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2021)

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
por: Porter, John, et al.
Publicado: (2008)

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange
por: Gattermann, Norbert, et al.
Publicado: (2012)

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
por: Ricchi, Paolo, et al.
Publicado: (2015)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Deferasirox: Duodenal perforation: case report
Publicado: (2021)

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes
por: Meunier, Mathieu, et al.
Publicado: (2017)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
por: Porter, John, et al.
Publicado: (2012)

Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review
por: Scoglio, Martin, et al.
Publicado: (2021)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2023)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

Should we move to a genomic classification of neutrophilic myeloid neoplasms?
por: Carreño-Tarragona, Gonzalo, et al.
Publicado: (2023)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Deferasirox – a rarer cause of Fanconi syndrome
por: Khan, Iman, et al.
Publicado: (2019)

Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
por: Gascon, Jose Miguel, et al.
Publicado: (2019)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Non-Enzymatic Modification of Aminophospholipids by Carbonyl-Amine Reactions
por: Naudí, Alba, et al.
Publicado: (2013)

High-Throughput CRISPR Screening in Hematological Neoplasms
por: Ancos-Pintado, Raquel, et al.
Publicado: (2022)

Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD
por: Vilorio-Marqués, Laura, et al.
Publicado: (2022)

MPL S505C enhances driver mutations at W515 in essential thrombocythemia
por: Varghese, Leila N., et al.
Publicado: (2021)

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
por: Blanco Sánchez, Alberto, et al.
Publicado: (2023)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l5fcamhs8mbn4h0c2argsi1sck